Manila Times Business
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat
STOCKHOLM, June 17, 2026 /PRNewswire/ -- Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190 patients have been randomized in its Phase 2 clinical proof-of-concept trial (NOVA). The study is evaluating vipoglanstat, a novel, non-hormonal, non-opioid drug candidate for the treatment of endometriosis. This painful, often debilitating, chronic inflammatory disease, which affects more than 10 % of
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
P15-B supplemental budget for Mindanao quake relief, recovery filed
Just now
LEIFRAS Co., Ltd. Issues JPY200 Million SDGs Private Placement Bonds to Establish Robust Financial Foundation and Support Disadvantaged Youth
Just now
Divine Adili's public wake ends as Ateneo prepares send-off mass for Nigerian player
Just now
TOMI Advances Toward NSF Certification to Address Multi-Billion-Dollar Pharmaceutical, Biotech and Cleanroom Decontamination Markets
Just now